Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study
These results support the use of ruxolitinib in patients with myelofibrosis, regardless of baseline anemia or development of treatment-related anemia.
Authors
- Paola Guglielmelli (ORCID: https://orcid.org/0000-0003-1809-284X)
- Ruben A. Mesa (ORCID: https://orcid.org/0000-0001-5880-7972)
- Claire N. Harrison (ORCID: https://orcid.org/0000-0002-3212-920X)
- Haifa Kathrin Al‐Ali (ORCID: https://orcid.org/0000-0001-5009-2239)
- J.E. Hamer-Maansson
- Evan Braunstein
- Vikas Gupta
Institutions
- Atrium Health Wake Forest Baptist (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Princess Margaret Cancer Centre (CA)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University Hospital in Halle (DE)
- Incyte (United States) (US)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1159/000546585
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Incyte